articleMMWR Morbidity and Mortality Weekly ReportFeb 1, 2024DIAMOND OA

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

RLRuth Link‐GellesAAAllison Avrich CieslaJMJosephine MakJDJoseph D. MillerBJBenjamin J. Silk
PubMed
Indexed incrossrefpubmed

Abstract

On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to prevent COVID-19, including severe disease. During fall 2023, XBB lineages co-circulated with JN.1, an Omicron BA.2.86 lineage that emerged in September 2023. These variants have amino acid substitutions that might increase escape from neutralizing antibodies. XBB lineages predominated through December 2023, when JN.1 became predominant in the United States. Reduction or failure of spike gene (S-gene) amplification (i.e., S-gene target failure [SGTF]) in real-time reverse transcription-polymerase chain…

Citation impact

166
total citations
FWCI
59.14
Percentile
100%
References
10
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Medicine
  • Vaccination
  • Coronavirus disease 2019 (COVID-19)
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Virology
  • Immunization
  • Internal medicine
  • Immunology
No related works found for this paper.

Funding